Nature Reviews Cancer

Papers
(The TQCC of Nature Reviews Cancer is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Linking pancreatic renewal and cancer initiation1419
Computing brain metastasis impact1198
Digging for treasures in the tumour interactome998
INVADEseq to study the intratumoural microbiota at host single-cell resolution869
An inhospitable site528
Fructose takes a detour to feed cancer517
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment487
Emerging strategies to investigate the biology of early cancer451
Combinatorial strategies to target RAS-driven cancers422
Artificial intelligence in cancer research, diagnosis and therapy385
Oncofetal reprogramming in tumour development and progression379
Mapping the prostate cell family tree338
How medical anthropology can contribute to cancer research320
Tertiary lymphoid structures as hubs of antitumour immunity319
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma301
Connie J. Eaves (1944–2024)281
Antihistamines boost immunotherapy274
The recruitment of metastasis-associated monocytes274
Fighting cancer with fat267
Translating premalignant biology to accelerate non-small-cell lung cancer interception253
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’252
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel248
Targeting transcription cycles in cancer246
Context-dependent functions of pattern recognition receptors in cancer227
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies225
Epithelial and stromal co-evolution and complicity in pancreatic cancer222
Impersonating neurons217
No mutation, tumour initiation217
Under pressure211
Nanoreceptors take down mutant p53204
Measuring HLA disruption using MHC Hammer202
Gut microbes produce novel genotoxic metabolites198
Tumour EVPs disrupt liver function198
Dendritic cells rise and shine196
Removing barriers to address sex differences in anticancer drug toxicity183
Persistence is key174
Thelpers? More like Ttroublemakers164
Defining a ‘cells to society’ research framework for appendiceal tumours161
Remodelling of the tumour microenvironment by the kallikrein-related peptidases160
Tumour–host interactions through the lens of Drosophila159
Cancer stem cell–immune cell crosstalk in tumour progression158
3D bioprinted cancer models: from basic biology to drug development157
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer156
Natural killer cells in antitumour adoptive cell immunotherapy152
How chemokines organize the tumour microenvironment151
Points of entry for tumour-infiltrating lymphocytes150
B-ring sterols to the rescue144
Identifying spatial cellular structures with SPACE-GM141
Bone voyage: immune crosstalk sets sail141
In-depth organoid profiling of pancreatic cancer140
Visualizing intratumoural heterogeneity with EpicMIBI140
Metabolic interplays between the tumour and the host shape the tumour macroenvironment133
Un-Fair Skin: racial disparities in acral melanoma research131
Leveraging the replication stress response to optimize cancer therapy125
The path to leptomeningeal metastasis125
Linking cell mechanical memory and cancer metastasis122
The plasticity of mRNA translation during cancer progression and therapy resistance118
Dynamics and specificities of T cells in cancer immunotherapy116
In situ decellularization of tissues to resolve the tumour-associated matrix115
Deciphering the cancer genome and epigenome112
Understanding and addressing race disparities in childhood cancer outcomes110
Encoding spatial tumour dynamics with Starfysh101
Taming TAMs in brain metastases98
Race influences the tumour microbiome97
The link between vitamin D and prostate cancer97
Targeted protein degradation for cancer therapy94
Polygenic scores in cancer90
Cancer nanomedicine86
Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic85
Acetyl-CoA metabolism in cancer84
RNA splicing dysregulation and the hallmarks of cancer84
Z-nucleic acids give immunotherapy a boost83
Local CAR manufacturing81
Author Correction: Antibody-based proteomics: fast-tracking molecular diagnostics in oncology81
Parity modulates epithelial–immune cell communication80
Right ON target: a new RAS-GTP inhibitor79
Defining precancer: a grand challenge for the cancer community79
A trojan horse to target spliceosome mutant cells77
NOTUM-mediated stem cell competition in CRC77
Prime editing GEMMs to model cancer mutations76
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities74
Chromothripsis in cancer74
Integrative medicine in oncology: redefining the standard of care73
Targeting ferroptosis as a vulnerability in cancer71
Tertiary lymphoid structures in anticancer immunity71
Starting a new job69
Functional lineage tracing to study the clonal evolution of therapy resistance68
Glycogen condensates drive tumorigenesis by trapping Hippo kinases68
Neutrophils: a roadblock for immunotherapy68
Quantum probes in cancer research68
In vivo labelling system to study cell neighbourhoods65
Revealing genomic secrets of archival FFPE samples63
Judith Campisi (1948–2024)62
Inferring cancer metabolism from gene-expression data60
New pathogen on the block60
The present and future of the Cancer Dependency Map58
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data55
Recent advances in therapeutic cancer vaccines55
Cell states can give tumorigenesis a head start53
Carcinogenesis at single-cell resolution53
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart53
Bidirectional CART.BiTE cells bring new hope52
Microbiota links to immunotherapy toxicity52
Patient-derived organoids unveil sarcoma vulnerabilities51
Evolution and progression of Barrett’s oesophagus to oesophageal cancer45
Global post-mortem tissue donation programmes to accelerate cancer research45
Transfer RNAs as dynamic and critical regulators of cancer progression44
Developing dietary interventions as therapy for cancer44
A timeline of tumour-associated macrophage biology41
Traject3d for studying 3D cellular heterogeneity39
Epigenomic heterogeneity as a source of tumour evolution39
Author Correction: Integrative medicine in oncology: redefining the standard of care37
We cannot ignore the cancer risks of wildfires37
Harnessing the influenza virus to fight cancer35
Targeting cancer cell dormancy33
Tissue clearing to examine tumour complexity in three dimensions32
Digitally enhanced Raman spectroscopy32
0.35849595069885